Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
AMES, Iowa, Aug. 29, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following investor conferences in September:
- Baird Global Healthcare Conference on September 7 at 1:25pm ET in New York City
- Cantor Fitzgerald Global Healthcare Conference on September 25 at 4:10pm ET in New York City
A live webcast of both conference presentations will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events and Presentations."
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod is being evaluated in combination with treatment regimens including PD-1 checkpoint blockade, cancer vaccines, and chemotherapy across multiple indications such as melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer. For more information, please visit http://www.newlinkgenetics.com.
Investor Contact: Lisa Miller Director of Investor Relations NewLink Genetics (515) 598-2555 [email protected] Media Contact: Andrew Mastrangelo AVP, Public & Media Relations LaVoieHealthScience 617-374-8800, ext. 108 [email protected]
